Polaryx Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.86 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 92.71M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
Details
| Name | Polaryx Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 11 |
| Founded | 2014 |
| Ceo | Alex Yang |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US73110F1003 |
| Cusip | 73110F100 |
| Cik | 2075320 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Alex Yang J.D., L.L.M. | Chief Executive Officer and Chair of Board |
| G. Michael Landis CPA | Chief Financial Officer and Director |
| Andrew John O | Chief Investment Officer |
| Dr. Shrijay Vijayan M.B.A., Ph.D. | Chief Scientific and Business Development Officer |
| Wuxin Zhu P.M.P., Ph.D. | Chief Chemistry, Manufacturing and Controls Officer |
| Dr. Ralph William Charlton III, M.D. | Chief Medical Officer |
Contact
| Address | South Tower, 140 E Ridgewood Avenue, Paramus, New Jersey 07652, United States |
| Phone | 201 940 7236 |
| Website | https://polaryx.com |